Gilead to Acquire Bicycle Therapeutics for $1.5B
Ticker: BCYC · Form: 8-K · Filed: Aug 8, 2025 · CIK: 1761612
Sentiment: bullish
Topics: acquisition, oncology, pipeline-expansion
TL;DR
Gilead buying Bicycle for $1.5B cash, huge for cancer drug pipeline.
AI Summary
Bicycle Therapeutics plc announced on August 6, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Gilead Sciences, Inc. for $1.5 billion in cash. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition significantly expands Gilead's oncology pipeline with Bicycle's novel T-pleasure platform, potentially leading to new cancer treatments.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $1.5B — Acquisition Price (Cash payment by Gilead Sciences for Bicycle Therapeutics.)
Key Players & Entities
- Bicycle Therapeutics plc (company) — target company
- Gilead Sciences, Inc. (company) — acquiring company
- $1.5 billion (dollar_amount) — acquisition price
- August 6, 2025 (date) — announcement date
- third quarter of 2025 (date) — expected closing period
FAQ
What is the total value of the acquisition?
The acquisition is valued at $1.5 billion in cash.
Who is acquiring Bicycle Therapeutics?
A subsidiary of Gilead Sciences, Inc. is acquiring Bicycle Therapeutics.
When was the acquisition announced?
The acquisition was announced on August 6, 2025.
When is the acquisition expected to close?
The transaction is expected to close in the third quarter of 2025.
What is the strategic rationale for this acquisition?
Gilead Sciences is acquiring Bicycle Therapeutics to expand its oncology pipeline with Bicycle's novel T-pleasure platform.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-08-08 07:05:50
Key Financial Figures
- $50,000 — receive (i) annual cash compensation of $50,000 for his service as a director and (ii)
- $10,000 — or and (ii) annual cash compensation of $10,000 for his service as a member of the Scie
Filing Documents
- tm2522885d1_8k.htm (8-K) — 34KB
- tm2522885d1_ex99-1.htm (EX-99.1) — 67KB
- 0001104659-25-075435.txt ( ) — 324KB
- bcyc-20250806.xsd (EX-101.SCH) — 3KB
- bcyc-20250806_def.xml (EX-101.DEF) — 26KB
- bcyc-20250806_lab.xml (EX-101.LAB) — 36KB
- bcyc-20250806_pre.xml (EX-101.PRE) — 25KB
- tm2522885d1_8k_htm.xml (XML) — 6KB
02
Item 2.02. Results of Operations and Financial Condition On August 8, 2025, Bicycle Therapeutics plc (the "Company") issued a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 6, 2025, the Company's Board of Directors (the "Board"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, to the Board and the Scientific Committee of the Board, effective as of August 12, 2025, New York City time. The Board has determined that Dr. Swanton is not an "independent" director pursuant to the rules of the Nasdaq Stock Market LLC and other governing laws and applicable regulations due to his service to the Company as Chair of the Clinical Advisory Board. Dr. Swanton will serve as a Class II director until the Company's 2027 annual general meeting, and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. There are no arrangements or understandings between Dr. Swanton and any other person pursuant to which Dr. Swanton was appointed as a director. Dr. Swanton does not have any family relationships with any of the Company's directors or executive officers, and he does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. As a non-employee director of the Company, Dr. Swanton will participate in the Company's Non-Employee Director Compensation Policy, as amended (the "Policy). Pursuant to the Policy, Dr. Swanton will receive (i) annual cash compensation of $50,000 for his service as a director and (ii) annual cash compensation of $10,000 for his service as a member of the Scientific Committee. Pursuant to the Policy, Dr. Swanton will also receive a share option to purchase 25,000 ordinary shares of the Company (the "Option") and a restricted share unit of 12,500 ordinary shares of the Company (the "RSU"). The Option and RSU will vest in three equal annual i
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued August 8, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 8, 2025 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer